China Shineway Pharmaceutical Group Limited
2877
Rangering i aksjer
#11102
As an investment holding enterprise, China Shineway Pharmaceutical Group... As an investment holding enterprise, China Shineway Pharmaceutical Group Limited is dedicated to the development, production, and sale of traditional Chinese medicines throughout the People's Republic of China and Hong Kong. Its extensive product range includes modern Chinese pharmaceuticals delivered as soft capsules, granular preparations, and injectable forms, alongside specialized Traditional Chinese Medicine (TCM) Formula Granules. These offerings cater to a broad spectrum of therapeutic needs, such as cardiovascular and cerebrovascular health, anti-viral applications, orthopedic conditions, pediatric ailments, gynecological care, and gastrointestinal issues. Furthermore, the company is involved in the trading of agricultural commodities. Founded in 2004, its headquarters are situated in Shijiazhuang, PRC, and it functions as a subsidiary of Forway Investment Limited.
Aksjekurs
$0.93796319
Markedsverdi
$708.54M
Endring (1 dag)
-1.85%
Endring (1 år)
-95.13%
Land
CN
Handel China Shineway Pharmaceutical Group Limited (2877)
Kategori
Healthcare
Inntekter for China Shineway Pharmaceutical Group Limited (2877)
Inntekter i Oct 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til China Shineway Pharmaceutical Group Limited er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for China Shineway Pharmaceutical Group Limited fra 2026 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | - |
IN
|
